Key Points
- Septerna COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at $44 per share, reducing her ownership by 12.55% to 174,209 shares.
- Septerna reported better-than-expected quarterly results, with a loss of $0.29 per share versus the $0.43 consensus estimate and revenue of $26.75 million compared with expectations of $19.22 million.
- Analyst sentiment remains broadly positive: multiple firms raised price targets, and the stock carries a consensus “Moderate Buy” rating with an average target of $51.33.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) COO Elizabeth Bhatt sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total value of $1,100,000.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company's stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Septerna Stock Down 6.3%
NASDAQ:SEPN opened at $45.14 on Friday. Septerna, Inc. has a twelve month low of $10.74 and a twelve month high of $51.10. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -83.59 and a beta of 2.29. The stock's 50 day moving average price is $35.57 and its two-hundred day moving average price is $29.54.
Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.59% and a negative net margin of 24.51%.The company had revenue of $26.75 million during the quarter, compared to the consensus estimate of $19.22 million. As a group, analysts anticipate that Septerna, Inc. will post -1.54 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on SEPN. HC Wainwright lifted their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a "buy" rating in a research report on Wednesday. Wells Fargo & Company upped their target price on shares of Septerna from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday. JonesTrading raised their target price on shares of Septerna from $43.00 to $62.00 and gave the company a "buy" rating in a research note on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Septerna in a report on Friday, July 17th. Finally, Truist Financial boosted their price target on Septerna from $35.00 to $43.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $51.33.
View Our Latest Stock Analysis on Septerna
Key Septerna News
Here are the key news stories impacting Septerna this week:
- Positive Sentiment: JonesTrading raised its price target on Septerna from $43 to $62 and initiated a “buy” rating, implying substantial potential upside from recent trading levels. JonesTrading raises Septerna price target
- Positive Sentiment: HC Wainwright increased its target from $40 to $60 and maintained a “buy” rating, adding to the bullish analyst consensus. HC Wainwright raises Septerna price target
- Positive Sentiment: Wells Fargo raised its price target from $48 to $50 and kept an “overweight” rating, reflecting continued confidence in Septerna’s outlook. Wells Fargo raises Septerna price target
- Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: adjusted loss per share was $0.29 versus the $0.43 consensus loss, while revenue of $26.75 million surpassed estimates of $19.22 million. The results previously helped drive a sharp advance in the shares. Septerna shares rise on better-than-expected earnings
- Neutral Sentiment: Analysts also published broader commentary covering Septerna and Rapid7, but the available report details do not indicate a separate material change to Septerna’s outlook. Analyst insights on Septerna and Rapid7
- Negative Sentiment: COO Elizabeth Bhatt sold 25,000 Septerna shares for approximately $1.1 million, reducing her stake by 12.55%. Although she still owns a sizable position, the insider transaction may weigh on sentiment and encourage profit-taking after the stock’s recent rally. Septerna insider transaction filing
Hedge Funds Weigh In On Septerna
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC boosted its position in Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company's stock worth $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC bought a new position in shares of Septerna in the fourth quarter valued at about $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the 3rd quarter worth about $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Septerna during the 4th quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Septerna during the 4th quarter worth about $61,000.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
